Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

CSPC Pharmaceutical Group Ltd

Healthcare US CHJTF

NoneUSD
0.00(0%)

Last update at 2026-06-03T21:02:20.845374Z

Day Range

--
LowHigh

52 Week Range

0.781.39
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap17167.81M
  • VolumeNone
  • P/E Ratio27.80
  • Dividend Yield21.75%
  • EBITDA5046.06M
  • Revenue TTM26005.98M
  • Revenue Per Share TTM2.28
  • Gross Profit TTM 17058.50M
  • Diluted EPS TTM0.05

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 5213.32M 5578.73M 8225.13M 8835.15M 8225.15M
Minority interest - -10.79000M -187.92700M -140.66000M -82.93900M
Net income 4209.27M 4328.03M 5873.32M 6091.39M 5605.19M
Selling general administrative - 1079.60M 1189.65M 1172.84M 1009.82M
Selling and marketing expenses - 8662.31M 10055.95M 10337.42M 10443.42M
Gross profit 18496.10M 20298.71M 24397.35M 25881.50M 25472.25M
Reconciled depreciation - 1339.45M 1117.49M 1047.94M 865.47M
Ebit 4305.65M 5622.40M 7415.27M 7438.94M 8234.38M
Ebitda 5833.88M 6961.85M 8532.76M 8655.09M 9275.39M
Depreciation and amortization 1528.23M 1339.45M 1117.49M 1216.15M 1041.00M
Non operating income net other - - - - -
Operating income 4305.65M 5366.15M 7680.12M 7893.03M 7526.77M
Other operating expenses 23891.97M 23643.11M 26919.25M 28082.82M 26058.69M
Interest expense 41.85M 43.67M 25.90M 28.95M 9.24M
Tax provision - 1239.90M 1288.83M 1350.21M 1158.97M
Interest income - - - - -
Net interest income - -43.67300M -26.76800M -24.89100M -7.66400M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1010.25M 1239.90M 1454.93M 1570.13M 1396.81M
Total revenue 28197.63M 29009.25M 34599.37M 35975.85M 33585.46M
Total operating expenses 14190.45M 14932.57M 16717.23M 17988.47M 17945.48M
Cost of revenue 9701.52M 8710.54M 10202.02M 10094.35M 8113.21M
Total other income expense net 907.66M 212.58M 545.00M 942.12M 562.11M
Discontinued operations - - - - -
Net income from continuing ops - 4338.82M 6306.12M 6232.05M 5688.12M
Net income applicable to common shares - - - - 5605.19M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 52000.87M 44388.99M 46282.17M 41769.77M 34741.58M
Intangible assets 3089.98M 2609.51M 2198.55M 1908.11M 467.85M
Earning assets - - - - -
Other current assets 830.64M 569.43M -170.30935M - 177.75M
Total liab 13527.29M 10522.70M 11264.16M 10127.90M 7913.35M
Total stockholder equity 36945.84M 32264.69M 33203.21M 30197.53M 25986.67M
Deferred long term liab - - - 35.81M 41.98M
Other current liab 6769.96M 6235.60M 6323.21M 2519.83M 2251.98M
Common stock 12317.55M 11032.75M 12000.31M - 10899.41M
Capital stock - 11032.75M 10899.41M 10899.41M 10899.41M
Retained earnings - 23344.08M 28872.72M 23191.55M 19187.67M
Other liab - - - - 631.68M
Good will 261.58M 234.90M 234.90M 234.90M 149.98M
Other assets 0.00001M - -1973.36385M 1008.15M 942.49M
Cash 6781.09M 6777.20M 12015.22M 10298.01M 9283.64M
Cash and equivalents - - - - -
Total current liabilities 11333.65M 9634.03M 10182.57M 8958.00M 7226.04M
Current deferred revenue 737.45M - -8.31042M - -
Net debt -6067.17608M -6269.86900M -11308.32200M - -
Short term debt 512.70M 451.19M 599.84M - -
Short long term debt - 392.20M 450.22M 153.48M 0.00000M
Short long term debt total 713.91M 507.33M 706.90M - -
Other stockholder equity 24628.29M -2112.13700M -9227.58417M -4006.29600M -4061.60600M
Property plant equipment - - - - 9563.92M
Total current assets 24777.37M 21888.14M 26744.94M 23957.16M 20336.50M
Long term investments - - - - -
Net tangible assets - - - 28090.33M 25410.82M
Short term investments 3091.14M 1473.11M 1077.05M 3574.86M 1443.41M
Net receivables 10632.78M 9938.39M 10684.31M 3937.97M 6548.65M
Long term debt - - 0.00000M 28.95M -
Inventory 3441.72M 3130.01M 3138.66M 2554.86M 2480.37M
Accounts payable 3313.54M 2613.00M 2841.74M 2205.57M 1769.65M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - -7464.85600M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 619.68M 1529.24M 264.66M - -
Deferred long term asset charges - - - - -
Non current assets total 27223.51M 22500.85M 21510.59M 17812.61M 14405.07M
Capital lease obligations - 115.13M 256.69M 400.11M 94.04M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -3858.20000M 607.27M -4074.89000M 630.71M -450.05600M
Change to liabilities - - 487.07M 232.57M 629.28M
Total cashflows from investing activities - - -6795.98400M -637.32600M -2129.51300M
Net borrowings - - -135.23900M -222.16700M 76.68M
Total cash from financing activities -5253.33200M -2559.57700M -2222.97075M -2646.69990M -1650.77972M
Change to operating activities - - 920.34M -59.87200M 894.92M
Net income 5578.73M 7389.37M 7083.54M 6755.43M 5797.87M
Change in cash -4573.46900M 2489.99M 205.62M 2705.89M 3835.44M
Begin period cash flow 10490.84M 8000.85M 11356.36M 8650.47M 4815.03M
End period cash flow 5917.38M 10490.84M 11561.98M 11356.36M 8650.47M
Total cash from operating activities 4534.66M 4178.81M 9225.19M 5862.52M 7674.41M
Issuance of capital stock -510.06100M -258.59600M - - 0.00000M
Depreciation 1339.45M 1117.49M 1216.15M 1041.00M 906.92M
Other cashflows from investing activities -123.96000M 107.05M 48.61M 15.59M -20.37256M
Dividends paid 3233.82M 2726.25M 2438.51M 2037.73M 1716.66M
Change to inventory 8.65M -583.74600M -49.71304M -743.69591M 675.83M
Change to account receivables -446.43200M -3638.07220M -525.29418M -2313.48558M -51.14940M
Sale purchase of stock -1579.09800M -200.35800M -14.21100M -263.51200M -0.00000M
Other cashflows from financing activities 50.59M 653.47M 174.44M -246.46181M 76.68M
Change to netincome - - -310.38500M -446.11100M -909.02900M
Capital expenditures 2678.88M 1893.07M 3166.16M 2119.30M 1766.31M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -817.26300M -3031.83000M 928.12M -1672.73397M 1888.00M
Stock based compensation 210.45M 235.09M 160.73M 17.73M 9.13M
Other non cash items -1776.70300M -1531.30900M 2563.65M 4544.41M -108.69823M
Free cash flow 1855.79M 2285.75M 6059.03M 3743.22M 5908.11M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CHJTF
CSPC Pharmaceutical Group Ltd		 - -% - 27.80 7.54 0.66 2.39 3.13 16.79
LLY
Eli Lilly and Company		 14.63 1.37% 1078.78 78.14 31.95 16.34 45.83 16.65 54.36
JNJ
Johnson & Johnson		 0.35 0.16% 223.24 29.17 14.33 3.74 5.18 3.80 15.22
ABBV
AbbVie Inc		 1.73 0.80% 217.13 86.32 14.33 5.89 50.46 7.04 24.44
AZN
AstraZeneca PLC		 -1.17 0.66% 176.28 30.69 19.23 5.30 6.45 5.72 17.23

Reports Covered

Stock Research & News

View All

Profile

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. It also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, the company provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food products; and healthcare services. It has a strategic collaboration with AstraZeneca PLC to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple therapies for obesity and type 2 diabetes. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

CSPC Pharmaceutical Group Ltd

No.896 Zhongshandong Street, Shijiazhuang, China, 050035

Key Executives

Name Title Year Born
Mr. Dongchen Cai Exec. Chairman 1954
Mr. Cuilong Zhang Vice-Chairman & CEO 1969
Mr. Chunlei Li Exec. Director & Chief Scientist 1976
Mr. Kin Man Chak Exec. Director 1966
Mr. Weidong Pan Exec. Director 1970
Mr. Huaiyu Wang Exec. Director 1963
Mr. Zhenguo Wang Exec. Director 1970
Dr. Qingxi Wang Exec. Director 1966
Dr. Hao Jiang Exec. Director 1983
Mr. Jinxu Wang Sr. VP 1971

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions